These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
60 related articles for article (PubMed ID: 7491398)
1. Assessment of paroxetine-induced sexual dysfunction using the Changes in Sexual Functioning Questionnaire. Clayton AH; Owens JE; McGarvey EL Psychopharmacol Bull; 1995; 31(2):397-413. PubMed ID: 7491398 [TBL] [Abstract][Full Text] [Related]
2. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. Walker PW; Cole JO; Gardner EA; Hughes AR; Johnston JA; Batey SR; Lineberry CG J Clin Psychiatry; 1993 Dec; 54(12):459-65. PubMed ID: 8276736 [TBL] [Abstract][Full Text] [Related]
3. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. Baldwin D; Bridgman K; Buis C J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325 [TBL] [Abstract][Full Text] [Related]
4. Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Clayton AH; McGarvey EL; Clavet GJ; Piazza L Psychopharmacol Bull; 1997; 33(4):747-53. PubMed ID: 9493487 [TBL] [Abstract][Full Text] [Related]
5. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity. Zourková A; Cesková E; Hadasová E; Ravcuková B J Sex Marital Ther; 2007; 33(4):343-55. PubMed ID: 17541852 [TBL] [Abstract][Full Text] [Related]
6. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385 [TBL] [Abstract][Full Text] [Related]
7. Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Baldwin D; Moreno RA; Briley M Hum Psychopharmacol; 2008 Aug; 23(6):527-32. PubMed ID: 18536065 [TBL] [Abstract][Full Text] [Related]
8. Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study. Saiz-Ruiz J; Montes JM; Ibáñez A; Díaz M; Vicente F; Pelegrín C; Viñas R; Arias F; Carrasco JL; Ferrando L Hum Psychopharmacol; 2005 Aug; 20(6):435-40. PubMed ID: 16106478 [TBL] [Abstract][Full Text] [Related]
9. Evaluating changes in sexual functioning in depressed patients: sensitivity to change of the CSFQ. Bobes J; González MP; Bascarán MT; Clayton A; Garcia M; Rico-Villade Moros F; Banús S J Sex Marital Ther; 2002; 28(2):93-103. PubMed ID: 11894800 [TBL] [Abstract][Full Text] [Related]
10. [Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence]. Daléry J; Aubin V Encephale; 2001; 27(1):71-81. PubMed ID: 11294041 [TBL] [Abstract][Full Text] [Related]
11. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Montejo AL; Llorca G; Izquierdo JA; Rico-Villademoros F J Clin Psychiatry; 2001; 62 Suppl 3():10-21. PubMed ID: 11229449 [TBL] [Abstract][Full Text] [Related]
12. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. Thase ME; Clayton AH; Haight BR; Thompson AH; Modell JG; Johnston JA J Clin Psychopharmacol; 2006 Oct; 26(5):482-8. PubMed ID: 16974189 [TBL] [Abstract][Full Text] [Related]
13. Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders. Montejo AL; Rico-Villademoros F J Sex Marital Ther; 2008; 34(3):227-39. PubMed ID: 18398761 [TBL] [Abstract][Full Text] [Related]
14. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study. Anghelescu IG; Kohnen R; Szegedi A; Klement S; Kieser M Pharmacopsychiatry; 2006 Nov; 39(6):213-9. PubMed ID: 17124643 [TBL] [Abstract][Full Text] [Related]
15. Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). Keller A; McGarvey EL; Clayton AH J Sex Marital Ther; 2006; 32(1):43-52. PubMed ID: 16234225 [TBL] [Abstract][Full Text] [Related]
16. Time course of response to paroxetine: influence of plasma level. Gex-Fabry M; Gervasoni N; Eap CB; Aubry JM; Bondolfi G; Bertschy G Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):892-900. PubMed ID: 17395353 [TBL] [Abstract][Full Text] [Related]
17. [Psychotropic drug-induced changes in sexuality--frequency and relevance in psychiatric practice]. Strauss B; Gross J Psychiatr Prax; 1984 Mar; 11(2):49-55. PubMed ID: 6718602 [TBL] [Abstract][Full Text] [Related]
18. Recognition and assessment of sexual dysfunction associated with depression. Clayton AH J Clin Psychiatry; 2001; 62 Suppl 3():5-9. PubMed ID: 11229452 [TBL] [Abstract][Full Text] [Related]
19. Induction of mania in depression by paroxetine. Morishita S; Arita S Hum Psychopharmacol; 2003 Oct; 18(7):565-8. PubMed ID: 14533140 [TBL] [Abstract][Full Text] [Related]
20. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects. Zourková A; Hadasová E Gen Physiol Biophys; 2003 Mar; 22(1):103-13. PubMed ID: 12870705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]